/

Sociétés

Ve

Non vérifié

Veradermics

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversSantéSanté Publique

4 communiqués de presse

Voir tous les communiqués de presse

11/12/2025

Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral Minoxidil

Source

Émetteur

1.00

0

18/11/2025

Industrie

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Médecine - Divers

Veradermics Advances VDPHL01 in Phase 2/3 Clinical Trial for Female Pattern Hair Loss, Marking a Milestone in the Development of the Potential First-Ever Oral Prescription Treatment for Women

Source

Émetteur

1.00

0

16/10/2025

Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Men

Source

Émetteur

1.00

0

11/12/2024

Marché du travail

Santé

Santé Publique

Médecine - Divers

Industrie pharmaceutique

Biotechnologie

Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0